| 词条 | Eprosartan |
| 释义 |
| Watchedfields = changed | verifiedrevid = 461094389 | IUPAC_name = 4-({2-Butyl-5-[2-carboxy-2-(thiophen-2-ylmethyl)eth-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid | image = Eprosartan.svg | tradename = Teveten | Drugs.com = {{drugs.com|monograph|teveten}} | MedlinePlus = a601237 | pregnancy_category = | legal_status = | routes_of_administration = Oral | bioavailability = 15% (Eprosartan mesylate) | metabolism = not metabolized | elimination_half-life = 5 to 9 hours | excretion = Renal 10%, biliary 90% | IUPHAR_ligand = 588 | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 133040-01-4 | ATC_prefix = C09 | ATC_suffix = CA02 | PubChem = 5281037 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = DB00876 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 4444504 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 2KH13Z0S0Y | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D04040 | ChEBI_Ref = {{ebicite|correct|EBI}} | ChEBI = 4814 | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 813 | C=23 | H=24 | N=2 | O=4 | S=1 | molecular_weight = Eprosartan mesylate: 520.625 g/mol | SMILES = O=C(O)\\C(=C\\c1cnc(n1Cc2ccc(C(=O)O)cc2)CCCC)Cc3sccc3 | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+ | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = OROAFUQRIXKEMV-LDADJPATSA-N }}Eprosartan is an angiotensin II receptor antagonist used for the treatment of high blood pressure. It is marketed in the United States as Teveten by Abbvie, the spin-off of the pharmaceutical discovery division of Abbott Laboratories; it is marketed as Eprozar by Intas Pharmaceuticals in India, and by Abbott Laboratories elsewhere. The compound came into the Abbott Laboratories cardiovascular pipeline with its acquisition of Kos Pharmaceuticals in 2006, which had licensed it, along with "a range of hypertensive treatments", from the Biovail Corporation.[1] Eprosartan is sometimes paired with hydrochlorothiazide, whereupon it is marketed in the US as Teveten HCT and elsewhere as Teveten Plus. The drug acts on the renin–angiotensin system to decrease total peripheral resistance in two ways. First, it blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle, causing vascular dilatation. Second, it inhibits sympathetic norepinephrine production, further reducing blood pressure. As with other angiotensin II receptor antagonists, eprosartan is generally better tolerated than enalapril (an ACE inhibitor), especially among the elderly.[2] See also
References1. ^Anon., 2006, Abbott Laboratories: Kos Pharmaceuticals a wise buy, Datamonitor ResearchStore (online), November 8, 2006, see , accessed 29 January 2015. {{Angiotensin II receptor antagonists}}{{Angiotensin receptor modulators}}2. ^{{cite journal |vauthors=Ruilope L, Jäger B, Prichard B |title=Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial |journal=Blood Press. |volume=10 |issue=4 |pages=223–9 |year=2001 |pmid=11800061 |doi=10.1080/08037050152669747}} 4 : Angiotensin II receptor antagonists|Imidazoles|Thiophenes|Benzoic acids |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。